Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.

An expert pharmacist discusses how identifying high-risk patients and minimizing unnecessary dopamine-blocking therapy are key steps in reducing the incidence of tardive dyskinesia.

At 48 weeks, participants receiving the highest dose combination of 9 mg eloralintide and 15 mg tirzepatide achieved an ...

Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity. Highlighting the clinical impact ...

Pharmacists are moving well beyond the dispensing counter and are taking on active roles in managing patients alongside ...

Viral pathogens are increasingly recognized in up to 26% of adult CAP hospitalizations, with influenza and RSV historically ...

Brianne Porter, PharmD, MS, explores how pharmacists can deliver care to a population of women experiencing life-altering symptoms of urinary incontinence.

Similarly, a large cross-sectional study in China evaluating individuals who recovered from COVID-19 found that 42.2% exhibited hesitancy toward subsequent doses, with higher levels of pandemic ...

Pharmacy benefit manager (PBM) reform is gaining momentum nationwide, but experts caution that pharmacies, a cornerstone of ...

Four approved PrEP options now span daily pills and long-acting injections. The faculty review how each agent works and where daily oral PrEP succeeds or falls short in practice. In "The HIV PrEP ...

Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.